Biohaven
NYSE: BHVNConnecticut, US · Founded 2022 · 405 employees on LinkedIn · 3 known investors
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.
Founders & leadership
VC
Vlad Coric, M.D.inChairman & Chief Executive OfficerChairman & Chief Executive Officer at Biohaven Pharmaceuticals
Investors · 3
Competitors · 2
by search overlap
Biogen Idec47 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Seeking Alpha40 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Biohaven for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Biohaven do?
- Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.
- Who are Biohaven's investors?
- Biohaven's investors include Oberland Capital, RA Capital, Sixth Street.
- Where is Biohaven headquartered?
- Biohaven is headquartered in Connecticut, US.